Meta-Analysis of Chinese Traditional Medicine Bushen Huoxue Prescription for Endometriosis Treatment.
Meta-Analysis of Chinese Traditional Medicine Bushen Huoxue Prescription for Endometriosis Treatment.
复制标题
中药补肾活血方治疗子宫内膜异位症的Meta分析
DOI：
10.1155/2017/5416423
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Yu CQ
中科院分区：
文献类型：
--
作者：
Shan J;Cheng W;Zhai DX;Zhang DY;Yao RP;Bai LL;Cai ZL;Liu YH;Yu CQ
目的评价补肾活血方治疗子宫内膜异位症的有效性和安全性。方法采用Meta分析方法，检索7个数据库中自数据库建立之日起至2017年4月30日止的相关研究。随机对照试验（RCT），探讨了BSHXP的疗效和安全性子宫内膜异位症患者纳入。两名评估员独立审查每项试验。使用科克伦偏倚风险评估工具进行质量评估。结果在纳入的13项研究中，补阳还五汤的总有效率高于西医（RR，1.55; 95%CI，1.03-2.32; P = 0.04），但两种治疗方法的痛经缓解率无显著差异（RR，1.28; 95%CI，0.70-2.34; P = 0.42）。妊娠率也高于激素治疗组（RR，1.99; 95% CI，1.17-3.39; P = 0.01）。然而，BSHXP是否比西药更有效地减少囊肿仍然未知。结论本研究提供了补肾活血片治疗子宫内膜异位症的有效性和安全性的证据，但由于纳入的随机对照试验方法学质量较低，该证据尚不确定。我们的研究结果表明，BSHXP是一种替代药物治疗子宫内膜异位症，但它应在未来的临床研究进一步检查。
Objectives To evaluate the efficacy and safety of Bushen Huoxue prescription (BSHXP) for endometriosis. Methods A meta-analysis was performed, and studies were searched from the seven databases from the date of database establishment to April 30, 2017. Randomized controlled trials (RCTs) that explored the efficacy and safety of BSHXP for patients with endometriosis were included. Two assessors independently reviewed each trial. The Cochrane Risk of Bias assessment tool was used for quality assessment. Results In the 13 included studies, the total effectiveness rates of BSHXP were higher than those of Western medicine (RR, 1.55; 95% CI, 1.03–2.32; P = 0.04), but the dysmenorrhea alleviation rates of the two treatments did not significantly differ (RR, 1.28; 95% CI, 0.70–2.34; P = 0.42). The pregnancy rates of BSHXP were also higher than those of hormone therapy (RR, 1.99; 95% CI, 1.17–3.39; P = 0.01). However, whether BSHXP is more effective than Western medicine in diminishing endometriotic cyst remains unknown. Conclusions Our study provides evidence that BSHXP is effective and safe for endometriosis, but this evidence is inconclusive because of the low methodological quality of the included RCTs. Our findings suggest that BSHXP is an alternative drug for endometriosis, but it should be further examined in future clinical research.
登录
查看更多内容
影响因子：
6.7
作者：
通讯作者：
--
DOI：
10.5653/cerm.2016.43.4.215
发表时间：
2016-12
期刊：
Clinical and experimental reproductive medicine
影响因子：
--
作者：
Park SY;Kim SH;Chae HD;Kim CH;Kang BM
通讯作者：
Kang BM
DOI：
10.1530/rep-16-0052
发表时间：
2016-09
期刊：
Reproduction (Cambridge, England)
影响因子：
--
作者：
Greene AD;Lang SA;Kendziorski JA;Sroga-Rios JM;Herzog TJ;Burns KA
通讯作者：
Burns KA
影响因子：
8.8
作者：
Kim, H. S.;Kim, T. H.;Chung, H. H.;Song, Y. S.
通讯作者：
Song, Y. S.
影响因子：
28.5
作者：
Zhang J;Cao J;Li J;Zhang Y;Chen Z;Peng W;Sun S;Zhao N;Wang J;Zhong D;Zhang X;Zhang J
通讯作者：
Zhang J